Carvedilol
- Generic Name
- Carvedilol
- Brand Names
- Coreg
- Drug Type
- Small Molecule
- Chemical Formula
- C24H26N2O4
- CAS Number
- 72956-09-3
- Unique Ingredient Identifier
- 0K47UL67F2
- Background
Carvedilol is a racemic mixture where the S(-) enantiomer is both a beta and alpha-1 adrenoceptor blocker, and the R(+) enantiomer is an alpha-1 adrenoceptor blocker. It is currently used to treat heart failure, left ventricular dysfunction, and hypertension. The dual action of carvedilol is advantageous in combination therapies as moderate doses of 2 drugs have a decreased incidence of adverse effects compared to high dose monotherapy in the treatment of moderate hypertension.
Carvedilol was granted FDA approval on 14 September 1995.
- Indication
Carvedilol is indicated to treat mild to severe heart failure, left ventricular dysfunction after myocardial infarction with ventricular ejection fraction ≤40%, or hypertension.
- Associated Conditions
- Atrial Fibrillation, Chronic Stable Angina Pectoris, Hypertension, LVEF ≤40% Left ventricular dysfunction, NYHA Class I or II heart failure, Chronic heart failure with reduced ejection fraction (NYHA Class III), Chronic heart failure with reduced ejection fraction (NYHA Class IV)
Carvedilol SR Study for Biomarkers From Blood and Urine and Safety of in Patients With Heart Failure With Preserved Ejection Fraction
- Conditions
- Heart Failure With Preserved Ejection Fraction
- Interventions
- Drug: Placebo
- First Posted Date
- 2019-05-14
- Last Posted Date
- 2019-05-21
- Lead Sponsor
- Yonsei University
- Target Recruit Count
- 300
- Registration Number
- NCT03948685
- Locations
- 🇰🇷
Division of Cardiology, Severance Cardiovascular Hospital, Yonsei University College of Medicine, Seoul, Korea, Republic of
Treating Breast Cancer Patients Undergoing Trastuzumab Treatment with Carvedilol to Reduce Incidence of Heart Failure
- First Posted Date
- 2019-03-19
- Last Posted Date
- 2025-01-07
- Lead Sponsor
- Mayo Clinic
- Target Recruit Count
- 450
- Registration Number
- NCT03879629
- Locations
- 🇺🇸
Mayo Clinic, Phoenix, Arizona, United States
🇺🇸Mayo Clinic in Florida, Jacksonville, Florida, United States
🇺🇸Mayo Clinic in Rochester, Rochester, Minnesota, United States
Comparison of Carvedilol and Atorvastatin for Preventing of Contrast-Induced Nephropathy.
- Conditions
- Contrast-induced Nephropathy
- Interventions
- First Posted Date
- 2019-03-08
- Last Posted Date
- 2019-03-12
- Lead Sponsor
- rabab ahmed mohamed
- Target Recruit Count
- 144
- Registration Number
- NCT03867994
Carvedilol With Chemotherapy in Second Line Glioblastoma and Response of Circulating Tumor Cells
- First Posted Date
- 2019-03-04
- Last Posted Date
- 2021-09-24
- Lead Sponsor
- West Virginia University
- Target Recruit Count
- 4
- Registration Number
- NCT03861598
- Locations
- 🇺🇸
WVU Cancer Institute - Mary Babb Randolph Cancer Center, Morgantown, West Virginia, United States
Danish Trial of Beta Blocker Treatment After Myocardial Infarction Without Reduced Ejection Fraction
- Conditions
- Acute Myocardial InfarctionNon-ST Elevation Myocardial Infarction (nSTEMI)ST Elevation Myocardial Infarction
- Interventions
- First Posted Date
- 2018-12-19
- Last Posted Date
- 2025-04-06
- Lead Sponsor
- Bispebjerg Hospital
- Target Recruit Count
- 2760
- Registration Number
- NCT03778554
- Locations
- 🇩🇰
Bispebjerg Hospital, Dept. of Cardiology Y builing 67, 1.floor, Bispebjerg Bakke 23, Copenhagen, Denmark
Beta-blockers for Oesophageal Varices
- First Posted Date
- 2018-12-17
- Last Posted Date
- 2019-10-03
- Lead Sponsor
- King's College Hospital NHS Trust
- Target Recruit Count
- 1200
- Registration Number
- NCT03776955
- Locations
- 🇬🇧
Queen Elizabeth Hospital, Birmingham, United Kingdom
🇬🇧Royal London Hospital (Barts), London, United Kingdom
🇬🇧King's College Hosptial NHS Foundation Trust (Denmark Hill), London, United Kingdom
Adrenergic Blockers for Cardiac Changes in Early Parkinson's Disease (Protocol 53136)
- Conditions
- Symptomatic Parkinson DiseasePre-motor Parkinson DiseaseREM Sleep Behavior Disorder
- Interventions
- First Posted Date
- 2018-12-13
- Last Posted Date
- 2025-01-28
- Lead Sponsor
- Michele Tagliati, MD
- Target Recruit Count
- 15
- Registration Number
- NCT03775096
- Locations
- 🇺🇸
Michele L Lima Gregorio, Los Angeles, California, United States
Carvedilol for Prevention of Esophageal Varices Progression
- First Posted Date
- 2018-11-09
- Last Posted Date
- 2022-12-01
- Lead Sponsor
- Beijing Friendship Hospital
- Target Recruit Count
- 240
- Registration Number
- NCT03736265
- Locations
- 🇨🇳
Beijing Ditan Hospital Capital Medical University, Beijing, Beijing, China
🇨🇳The First Affiliated Hospital of Shanghai Jiao Tong University, Shanghai, Shanghai, China
🇨🇳Beijing Friendship Hospital, Beijing, Beijing, China
Propranolol, Carvedilol and Rosuvastatin in the Prevention of Variceal Bleeding in Cirrhotic Portal Hypertension
- Conditions
- CirrhosisPortal HypertensionVariceal Hemorrhage
- Interventions
- First Posted Date
- 2018-10-25
- Last Posted Date
- 2019-05-14
- Lead Sponsor
- Universidade Federal do Rio de Janeiro
- Target Recruit Count
- 80
- Registration Number
- NCT03720067
- Locations
- 🇧🇷
Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil
Effects of Carvedilol on Suppressing the Premature Ventricular Complex/Ventricular Tachycardia From Outflow Tract
- Conditions
- Outflow TractVentricular Premature ComplexesCarvedilol
- Interventions
- First Posted Date
- 2018-07-16
- Last Posted Date
- 2018-07-18
- Lead Sponsor
- Keimyung University Dongsan Medical Center
- Target Recruit Count
- 104
- Registration Number
- NCT03587558
- Locations
- 🇰🇷
Division of Cardiology, Department of Internal Medicine, Kyungpook National University Hospital, Daegu, Korea, Republic of
🇰🇷Seoul Asan Medical Center, Seoul, Korea, Republic of
🇰🇷Severance Cardiovascular Hospital, Seoul, Korea, Republic of
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.